Boston Scientific, Inc. (BSX) recently obtained a CE Mark on the Vercise Neural Navigator 5 Software with STIMVIEW XT technology. When used as an element of the Vercise Genus Deep Brain Stimulation (DBS) Systems, it can provide clinicians with simple and actionable data for efficient programming to treat Parkinson’s disease, essential tremor and dystonia.The latest development comes as a significant boost for the company’s Neuromodulation business. In July 2023, the software had received the FDA’s approval. ...